University Medical Center Groningen and RaySearch initiate collaboration within adaptive radiation therapy


RaySearch Laboratories AB has received an order for its RayStation® treatment
planning system from University Medical Center Groningen (UMCG) in Groningen,
the Netherlands. In conjunction with this, RaySearch and UMCG will also initiate
a new research collaboration project.

UMCG is one of the largest hospitals in the Netherlands and the largest employer
in the Northern Netherlands. More than 10,000 employees provide patient care,
are involved in medical education and perform cutting-edge scientific research,
focused on ‘healthy and active ageing’. Research and education at the UMCG are
funded through the University of Groningen, and the Faculty of Medical Sciences
functions as an integral part of the University. More than 3,400 students of the
University of Groningen study Medicine, Dentistry or Human Movement Sciences,
while more than 340 physicians are doing their specialty training at the state
of the art facilities of the UMCG.

RaySearch and the department of Radiation Oncology of UMCG have a longstanding
research cooperation that will now be focused on adaptive radiation therapy
using RayStation®. Adaptive therapy is an advanced form of radiation therapy
where the delivered dose is adjusted continuously during the course of treatment
to account for changes occurring in the patient’s anatomy. This has a
significant potential to increase the tumor control probability and at the same
time reduce the risk for side effects by sparing healthy tissue. UMCG and
RaySearch will now collaborate to introduce adaptive radiation therapy in
clinical practice and further refine and evaluate the methods involved.

“RaySearch is a pioneer in the development of advanced software tools for
radiation therapy and our longstanding cooperation is highly important for our
department. RayStation® is the leading tool on the market for adaptive radiation
therapy and we are very excited to start implementing this concept with a
significant potential to improve cancer care”, says Prof. Johannes A.
Langendijk, chair of the Department of Radiation Oncology at University Medical
Center Groningen.

“UMCG is a well-renowned clinic and have proven over the years that they
maintain an excellent standard in cancer research. I am therefore convinced that
this collaboration will be very fruitful and will make meaningful contributions
to the area of adaptive radiation therapy which is the most important new
concept in radiation therapy”, says Johan Löf, CEO of RaySearch. “

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions
into a flexible treatment planning system. It combines unique features such as
multi-criteria optimization tools with full support for 4D adaptive radiation
therapy. It also includes functionality such as RaySearch’s market-leading
algorithms for IMRT and VMAT optimization and highly accurate dose engines for
photon, electron and proton therapy. The system is built on the latest software
architecture and has a graphical user interface offering state-of-the-art
usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch’s
products are mainly sold through license agreements with leading partners such
as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products
have been launched through partners and RaySearch’s software is used at over
2,000 clinics in more than 30 countries. In addition, RaySearch offers the
proprietary treatment planning system RayStation® directly to clinics. RaySearch
was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and
the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

Attachments

10116163.pdf
GlobeNewswire